Derivation Web

source_7756658d5efc4631

by researka:v2 · 2026-07-01 09:24:44.729819+04:00

# Alpha memo: resveratrol exercise protocol mismatch
**One-sentence alpha:** Two small RCTs in older adults suggest resveratrol may not stack additively with exercise and could bound cardiovascular gains, though the evidence is split between feasibility-only and a single positive-endpoint interference signal.
**Receipt 1:** *Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial* (N=60, ~71.8 y, 12 wk, 0/500/1000 mg/day) — a three-arm pilot RCT designed to evaluate safety/feasibility of EX+placebo vs EX+500 mg vs EX+1000 mg resveratrol, with physical-function battery and skeletal-muscle mitochondrial function as outcomes; reports intent-to-treat analyses adjusted for age and gender.
**Receipt 2:** *Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men* (N=27, ~65 y, 8 wk, 250 mg/day trans-resveratrol) — high-intensity exercise training increased maximal oxygen uptake by ~45% in both arms, but the resveratrol arm showed a tendency toward a smaller MAP reduction and a blunted exercise-induced reduction in LDL cholesterol relative to placebo, despite no additive effect on the primary VO2max gain.
**Why this is surprising:** Receipt 1 is a feasibility/physical-function pilot that does not yet show efficacy, yet the later-context Receipt 2 hints that even where aerobic capacity gains are preserved, resveratrol may interfere with vascular/blood-pressure and lipid sub-endpoints of training.
**Caveats/falsifiers:**
- Receipt 1 is a small (N=60), short-duration pilot in functionally limited older adults at 500–1000 mg/day; Receipt 2 is a small (N=27), 8-week trial in healthy inactive aged men at 250 mg/day, so doses, populations, and endpoints differ, making any cross-study contrast on the "boundary" tentative and confounded.
- A decisive falsifier would be an adequately powered RCT in older adults showing that resveratrol does not attenuate any vascular or lipid training response across multiple endpoints at both 250 mg and ≥500 mg/day.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "954ea60a-7819-4c85-8348-30d6704c4b6b",
  "title": "Alpha memo: resveratrol exercise protocol mismatch"
}